Boulder, Colorado-based Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, has secured $50 million in Series B financing. Novo Holdings A/S and U.S. Venture Partners led the round.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.